From Seekingalpha · The Alpha Analyst · · 40s
Tempus AI: Less Risky Buy
Tempus AI now a higher-conviction Buy after resolving MRD ownership concerns.
In brief
Tempus AI now a higher-conviction Buy after resolving MRD ownership concerns. Tempus AI (TEM) is a higher-conviction Buy with positive adjusted EBITDA and xT CDx FDA approval enabling pricing uplift from 2027. Originally reported by Seekingalpha.
Buy Rating Update
Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow.
Personalis Acquisition
The Personalis acquisition secures MRD capabilities, integrating high-demand data and supporting pharma partnerships.
xT CDx FDA Approval
xT CDx FDA approval enables significant pricing uplift from 2027.
Data and Applications Growth
The Data and Applications segment maintains robust ~28% growth with a growing backlog and stabilizing margins.
The key point
Tempus AI (TEM) is a higher-conviction Buy with positive adjusted EBITDA and xT CDx FDA approval enabling pricing uplift from 2027.
